Blau Farmaceutica SA
BOVESPA:BLAU3

Watchlist Manager
Blau Farmaceutica SA Logo
Blau Farmaceutica SA
BOVESPA:BLAU3
Watchlist
Price: 14.7 BRL -2.13% Market Closed
Market Cap: 2.6B BRL
Have any thoughts about
Blau Farmaceutica SA?
Write Note

Net Margin
Blau Farmaceutica SA

11.1%
Current
21%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
11.1%
=
Net Income
187m
/
Revenue
1.7B

Net Margin Across Competitors

Country Company Market Cap Net
Margin
BR
Blau Farmaceutica SA
BOVESPA:BLAU3
2.6B BRL
11%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
312.7B USD
9%
US
Amgen Inc
NASDAQ:AMGN
158.3B USD
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD
-5%
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD
0%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
133.6B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.5B EUR
-14%
Country BR
Market Cap 2.6B BRL
Net Margin
11%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 312.7B USD
Net Margin
9%
Country US
Market Cap 158.3B USD
Net Margin
13%
Country US
Market Cap 115.9B USD
Net Margin
-5%
Country US
Market Cap 112.4B USD
Net Margin
0%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 133.6B AUD
Net Margin
18%
Country US
Market Cap 82.6B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 34.5B EUR
Net Margin
-14%
No Stocks Found

Blau Farmaceutica SA
Glance View

Market Cap
2.6B BRL
Industry
Biotechnology

Blau Farmacêutica SA engages in the manufacturing of pharmaceuticals. The company is headquartered in Cotia, Sao Paulo and currently employs 1,700 full-time employees. The company went IPO on 2021-04-19. The firm focuses on the development, production and commercialization of medicines, which aim at treatment in the areas of oncology, nephrology, hematology and infectology, among others. Its product lines includes biopharmaceuticals, biosimilars, oncological - injectable, oncological - oral, blood products, antiviral and antiretrovirals, uterine stimulators, anaesthetics, antithrombotics, thrombolytics, female health care, antibiotics, non-beta lactams, cephalosporin, chloramphenicol, acid pumper inhibitor and other hospital products. The firm operates in Brazil, Argentina, Colombia, Peru, Uruguay, Chile and the United States, having a pharmaceutical industrial complex composed of five industrial plants, dedicated to the production of biological, biotechnological and oncological medicines, antibiotics, injectable anesthetics and biotechnological inputs.

BLAU3 Intrinsic Value
23.42 BRL
Undervaluation 37%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
11.1%
=
Net Income
187m
/
Revenue
1.7B
What is the Net Margin of Blau Farmaceutica SA?

Based on Blau Farmaceutica SA's most recent financial statements, the company has Net Margin of 11.1%.